CABALETTA BIO, INC. Operating Lease, Expense
CABALETTA BIO, INC. (CABA) reported Operating Lease, Expense of $578.00 thousand for the 6-month period ending 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-11-09
- CABALETTA BIO, INC. operating lease, expense for the quarter ending 2023-06-30 was $98.00K.
- CABALETTA BIO, INC. operating lease, expense for the quarter ending 2023-03-31 was $480.00K.
- CABALETTA BIO, INC. operating lease, expense for fiscal 2021 was $752.00K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2023-06-30 | $98.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $578.00K 10-Q · filed 2023-08-10 | ||
| 2023-03-31 | $480.00K 10-Q · filed 2023-05-11 | |||
| 2022-09-30 | $1.13M 10-Q · filed 2023-11-09 | |||
| 2021-12-31 | $752.00K 10-K · filed 2023-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |